Last updated on December 2014

EINSTEIN CHOICE


Brief description of study

EINSTEIN CHOICE

Detailed Study Description

EINSTEIN CHOICE is a phase II study designed to evaluate whether once-daily rivaroxaban in doses of 10mg or 20mg is superior to aspirin for the prevention of symptomatic recurrent DVT and/or PE in patients who have completed between six and 12 months of anticoagulant therapy. The study will include approximately 2,850 patients in 31 countries and currently is enrolling participants.

Clinical Study Identifier: TX139798

Contact Investigators or Research Sites near you

Start Over

Rebecca Palermo

UNC Rex Healthcare
Raleigh, NC USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.